Abstract
Purpose
SJG-136 is a pyrrolobenzodiazepine dimer that forms DNA crosslinks and has demonstrated broad antitumor activity. We undertook this trial to determine the maximum-tolerated dose (MTD), toxicities and pharmacokinetic (PK) profile of SJG-136 in patients with an advanced solid tumor.
Patients and methods
In this phase I study, patients were treated with SJG-136 on days 1, 8 and 15 of a 28-day cycle. Dose levels studied were 10, 20, 40 and 60 μg/m2. PK parameters of SJG-136 were assessed following the intravenous administration of SJG-136 on days 1 and 15 of cycle 1.
Results
Twenty-one patients with advanced solid tumors were treated. Patients had a median of two prior chemotherapy regimens. Fatigue was dose-limiting with SJG-136 60 μg/m2/day administered on days 1, 8 and 15 of a 28-day cycle. Grade 3 thrombocytopenia and delayed onset liver toxicity were seen in one patient each. PK parameters of SJG-136 indicated dose-proportional increases in systemic exposure with increasing doses. No objective responses were seen.
Conclusion
For patients with advanced solid tumors, the MTD of SJG-136 is 40 μg/m2/day administered on days 1, 8 and 15 of a 28-day cycle. The major dose limiting toxicity was fatigue. Alternative dosing strategies are now being evaluated.
Similar content being viewed by others
References
Puvvada MS, Hartley JA, Jenkins TC et al (1993) A quantitative assay to measure the relative DNA-binding affinity of pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumour antibiotics based on the inhibition of restriction endonuclease BamHI. Nucleic Acids Res 21(16):3671–3675
Puvvada MS, Forrow SA, Hartley JA et al (1997) Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines. Biochemistry 36(9):2478–2484
Gregson SJ, Howard PW, Hartley JA et al (2001) Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine dna-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem 44(5):737–748
Thurston DE (1993) Advances in the study of pyrrolo[2,1-c] [1,4]-benzodiazepine (PBD) antitumour antibiotics. In: Neidle S, Waring MJ (eds) Molecular aspects of anticancer drug–DNA interactions. The Macmillan Press Ltd, London, pp 64–88
Paull KD, Shoemaker RH, Hodes L et al (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81(14):1088–1092
Alley MC, Hollingshead MG, Pacula-Cox CM et al (2004) SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2. Efficacy evaluations. Cancer Res 64(18):6700–6706
Hartley JA, Spanswick VJ, Brooks N et al (2004) SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad-spectrum antitumor activity. Part 1. Cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 64(18):6693–6699
Wade Calcutt M, Lee W, Puzanov I et al (2008) Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom 43(1):42–52
Puzanov I, Lee W, Berlin JD et al (2008) Final results of phase I and pharmacokinetic trial of SJG-136 administered on a daily × 3 schedule. J Clin Oncol (Meeting Abstracts) 26(15_suppl):2504
Hochhauser D, Meyer T, Spanswick VJ et al (2009) Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin Cancer Res 15(6):2140–2147
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by CTEP, NIH 5U01CA069856-15; NCI-sponsored trial # 6818.
Rights and permissions
About this article
Cite this article
Janjigian, Y.Y., Lee, W., Kris, M.G. et al. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol 65, 833–838 (2010). https://doi.org/10.1007/s00280-009-1088-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-1088-4